The Evolving Treatment Paradigm for Osteoporosis: The Integral Role of the Pharmacist in Optimizing Care, featuring a Patient Perspective

Activity Add On

This program includes patient perspective videos.

Program Description

More than 2 million fractures occur each year in the United States due to osteoporosis. Increasing age and female sex are significant risk factors for developing osteoporosis. Through pharmacologic and nonpharmacologic interventions, pharmacists can be integral in the prevention and treatment of osteoporosis and its related fractures. This panel discussion will center on updates to the 2020 AACE/ACE guidelines for osteoporosis, as well as advances in treatment options and the role of pharmacists in supporting screening recommendations for patients to identify fracture risk. Indications, dosing, and clinical trial information for select available and emerging oral and parenteral therapies for osteoporosis will be discussed. Expert panelists will share tips to improve communication with patients about initiation of therapy and counseling points to educate patients on the importance of maintaining a bone healthy lifestyle and preventing development of fractures related to osteoporosis. This program features a patient perspective interview that will highlight the experience and challenges of a patient living with osteoporosis. 

Target audience: Health-system pharmacists, retail pharmacists, specialty pharmacists

Type of activity: Application
Release date: May 31, 2022
Expiration date: May 31, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain specific risk factors for fracture and the clinical, economic, and quality-of-life burden of osteoporosis
• Analyze updated AACE/ACE guidelines for the classification of fracture risk and recommendations for drug therapy
• Examine new and emerging therapies for osteoporosis, including mechanism of action, administration, safety and efficacy data, real-world evidence, and comparison studies
• Identify the role of the pharmacist in optimizing care for patients with osteoporosis, including appropriate counseling, the management of adverse effects, and monitoring

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-268-H01-P. The activity is available for CE credit through May 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the panel discussion in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Felicia Cosman, MD, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: Radius Health
• Consultant: Enterabio, Pfizer/Myovant, Obseva
• Speakers Bureau: Amgen, Radius Health

Michael P. Kane, PharmD, FCCP, BCPS, BCACP, has the following relevant financial relationship with a commercial interest to disclose:

• Grant/Research Support: Radius Pharmaceuticals

Andrea J. Singer, MD, FACP, CCD, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: Radius Health, UCB
• Consultant: Agnovos, Amgen, Radius Health, UCB
• Speakers Bureau: Amgen, Radius Health

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms